Vol. 150, No. 52 — December 24, 2016

GOVERNMENT NOTICES

DEPARTMENT OF CITIZENSHIP AND IMMIGRATION

IMMIGRATION AND REFUGEE PROTECTION ACT

Ministerial Instructions with respect to the processing of applications for permanent residence made by a foreign national as a sponsored spouse, common-law partner, conjugal partner or dependent child and the processing of sponsorship applications made in relation to those applications

These Instructions are published in the Canada Gazette in accordance with subsection 87.3(6) of the Immigration and Refugee Protection Act. These Instructions are given by the Minister of Citizenship and Immigration as, in the opinion of the Minister, these Instructions will best support the attainment of the immigration goals established by the Government of Canada by supporting the Government’s commitment to reduce processing times for applications made by foreign nationals as members of the Family Class and the Spouse or Common-law Partner in Canada Class.

Scope

These Instructions are given pursuant to section 87.3 and subsections 92(1.1) and (2) of the Immigration and Refugee Protection Act (IRPA).

These Instructions apply to the applications for a permanent resident visa of the sponsor’s spouse, common-law partner, conjugal partner or dependent child made under the Family Class and to applications to remain in Canada as a permanent resident of the sponsor’s spouse or common-law partner made under the Spouse or Common-Law Partner in Canada Class referred to in paragraphs 117(1)(a) and (b) and section 124 of the Immigration and Refugee Protection Regulations (IRPR), respectively — as well as any sponsorship applications made in relation to those applications — that are received by the Department of Citizenship and Immigration (the Department) as of December 15, 2016.

Condition

In order to be processed, any application referred to in these Instructions that has not been returned under section 12 of the IRPR for not meeting the requirements of sections 10 and 11 of the IRPR — for example by not using all the applicable forms provided by the Department in the application package published on the website of the Department at the time the application is received by the Department or by not including all information, documents and evidence referred to in paragraph 10(1)(c) of the IRPR — must meet the condition of being accompanied by the following documents:

Disposition of applications

Any application referred to in these Instructions that does not meet the condition established in these Instructions will be returned, except the application made in accordance with the previous application package published on the website of the Department that is received by the Department during the period commencing on the day on which these Instructions take effect and ending on January 31, 2017.

Coming into effect

These Instructions take effect on December 15, 2016.

Ottawa, December 12, 2016

John McCallum
Minister of Citizenship and Immigration

[52-1-o]

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Ministerial Condition No. 18685

Ministerial condition

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

Whereas the Minister of the Environment and the Minister of Health have assessed information pertaining to the substance 1-propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-C8-18 acyl derivs., inner salts, Chemical Abstracts Service No. 97862-59-4;

And whereas the ministers suspect that the substance is toxic or capable of becoming toxic within the meaning of section 64 of the Canadian Environmental Protection Act, 1999,

The Minister of the Environment, pursuant to paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999, hereby permits the manufacture or import of the substance in accordance with the conditions of the following annex.

George Enei
Assistant Deputy Minister
Science and Technology Branch
On behalf of the Minister of the Environment

ANNEX

Conditions

(Paragraph 84(1)(a) of the Canadian Environmental Protection Act, 1999)

1. The following definitions apply in these ministerial conditions:

“engineered hazardous waste landfill facility” means a facility that is part of an overall integrated hazardous waste management system where wastes that do not require additional treatment or processing are sent and where hazardous materials are confined or controlled for the duration of their effective contaminating lifespan;

“notifier” means the person who has, on July 19, 2016, provided to the Minister of the Environment the prescribed information concerning the substance, in accordance with subsection 81(1) of the Canadian Environmental Protection Act, 1999;

“substance” means 1-propanaminium, 3-amino-N-(carboxymethyl)-N,N-dimethyl-, N-C8-18 acyl derivs., inner salts, Chemical Abstracts Service No. 97862-59-4; and

“waste” means the effluents that result from rinsing equipment or vessels used for the substance, disposable vessels used for the substance, any spillage that contains the substance, the process effluents that contain the substance, and any residual quantity of the substance in any equipment or vessel.

2. The notifier may import or manufacture the substance in accordance with the present ministerial conditions.

Restriction

3. The notifier shall not import or manufacture the substance, unless

Handling of the substance

4. The notifier or the person to whom the substance has been transferred shall not release the substance or waste to the environment.

Disposal of the substance

5. The notifier or the person to whom the substance has been transferred must collect any waste in their physical possession or under their control and destroy or dispose of it in the following manner:

Environmental release

6. Where any release of the substance or waste to the environment occurs, the person who has the physical possession or control of the substance or waste shall immediately take all measures necessary to prevent any further release, and to limit the dispersion of any release. Furthermore, the person shall, as soon as possible in the circumstances, inform the Minister of the Environment by contacting an enforcement officer designated under the Canadian Environmental Protection Act, 1999.

Record-keeping requirements

7. (1) The notifier shall maintain electronic or paper records, with any documentation supporting the validity of the information contained in these records, indicating

(2) The notifier shall maintain electronic or paper records mentioned in subsection (1) at their principal place of business in Canada, or at the principal place of business in Canada of their representative, for a period of at least five years after they are made.

Other requirements

8. The notifier shall inform any person to whom they transfer the physical possession or control of the substance or of the waste, in writing, of the terms of the present ministerial conditions. The notifier shall obtain, prior to the first transfer of the substance or waste, written confirmation from this person that they were informed of the terms of the present ministerial conditions. This written confirmation shall be maintained at the principal place of business in Canada of the notifier or of their representative in Canada for a period of at least five years from the day it was received.

Coming into force

9. These ministerial conditions come into force on December 7, 2016.

[52-1-o]

DEPARTMENT OF HEALTH

CONTROLLED DRUGS AND SUBSTANCES ACT

Notice to interested parties — Proposed order amending Schedule III to the Controlled Drugs and Substances Act and proposed regulations amending the schedule to Part G of the Food and Drug Regulations to expand the scheduling entry for aminorex and its salts

This notice provides interested stakeholders with the opportunity to comment on Health Canada’s intent to amend Schedule III to the Controlled Drugs and Substances Act (CDSA) in order to expand the scheduling entry for aminorex and its salts to include its derivatives, isomers and analogues, as well as salts of the derivatives, isomers and analogues. The listing of aminorex and its salts will be similarly expanded in Part 1 of the schedule to Part G of the Food and Drug Regulations (FDR). In the interest of clarity, 4-MAR and 4,4′-DMAR, both of which are analogues of aminorex, would also be listed in these schedules to the CDSA and to Part G of the FDR. The current entry of 4-MAR and its salts will be removed from the schedule to Part J to the FDR.

Aminorex and its salts are currently controlled under Schedule III to the CDSA and Part G of the FDR. The derivatives, isomers and analogues of aminorex (as well as salts of derivatives, isomers and analogues) currently have no approved therapeutic uses in Canada; however, Health Canada is proposing to also list them under Part G of the FDR, which would facilitate legitimate use in the future, should therapeutic uses emerge. This expansion of the listing of aminorex and its salts would capture 4,4′-DMAR, an analogue of aminorex, which was added to Schedule II to the Convention on Psychotropic Substances, 1971 at the 59th Commission on Narcotic Drugs in Vienna, Austria, in March 2016. This regulatory amendment will ensure Canada meets its international obligations.

Available data suggests that there is a potential for abuse and/or addiction to 4,4′-DMAR. The substance is reported to have numerous toxic effects, including risk of death, and has been linked to 46 deaths internationally.

The CDSA is the legislation through which the Government of Canada fulfills its international obligations under the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. The CDSA and its regulations provide a legislative framework for the control of substances that can alter mental processes and that may cause harm to individuals or to society when diverted to an illicit market or use. The CDSA and its regulations have the dual purpose of protecting public health and maintaining public safety by permitting access to these substances for legitimate industrial, medical or scientific purposes, while mitigating the risks of trafficking and diversion to illicit markets and uses.

Part G of the FDR provides a licensing and permitting framework authorizing licensed dealers to conduct activities with substances specified on their licences. For example, only licensed dealers are authorized to engage in activities such as production, manufacture, assembly, importation, exportation, sale, provision, delivery or transportation of controlled substances.

The publication of this notice in the Canada Gazette, Part I, initiates a 30-day comment period. Anyone interested in this process or anyone who has comments about this notice should contact Legislative and Regulatory Affairs, Controlled Substances Directorate, Healthy Environments and Consumer Safety Branch, Health Canada, by mail at Address Locator: 0302A, 150 Tunney’s Pasture Driveway, Ottawa, Ontario K1A 0K9, or by email at ocs_regulatorypolicy-bsc_politiquereglementaire@hc-sc.gc.ca.

December 24, 2016

Ana G. Renart
Director General
Controlled Substances Directorate

[52-1-o]

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

Name and position

Order in Council

National Energy Board

  • Temporary members

    • Ferguson, Don

    • Malo, Carole M.

    • Paquin, Marc



  • 2016-1107

  • 2016-1106

  • 2016-1108

Nunavut Court of Justice

  • Deputy Judges

    • Johnson, The Hon. Earl D.

    • Mitchell, The Hon. John K.

    • Schuler, The Hon. Virginia A.



  • 2016-1121

  • 2016-1122

  • 2016-1123

Shaw, The Hon. Douglas C.

  • Superior Court of Justice in and for the Province of Ontario

    • Judge

  • Court of Appeal for Ontario

    • Judge ex officio

  • 2016-1109

Warkentin, The Hon./L’hon. Bonnie R.

  • Superior Court of Justice in and for the Province of Ontario — Northwest Region

    • Regional Senior Judge

  • Court of Appeal for Ontario

    • Judge ex officio

  • 2016-1110

Whalen, The Hon.

  • Specific Claims Tribunal

    • Part-time member

  • 2016-1105

December 16, 2016

Diane Bélanger
Official Documents Registrar

[52-1-o]

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Two-year review of list of entities established pursuant to section 83.05 of the Criminal Code

Whereas subsection 83.05(9) (see footnote a) of the Criminal Code (see footnote b) requires the Minister of Public Safety and Emergency Preparedness to review the list established under subsection 83.05(1) (see footnote c) of that Act two years after its establishment, and every two years after that, to determine whether there are still reasonable grounds for an entity to remain a listed entity as set out in subsection 83.05(1) (see footnote d) of that Act;

Whereas, on July 23, 2016, 14 years had elapsed since the establishment of the list by the Regulations Establishing a List of Entities (see footnote e) pursuant to subsection 83.05(1) (see footnote f) of the Criminal Code (see footnote g);

And whereas, pursuant to subsection 83.05(9) (see footnote h) of the Criminal Code (see footnote i), the Minister of Public Safety and Emergency Preparedness has carried out the review of the list as it existed on July 23, 2016;

Therefore, notice is given, pursuant to subsection 83.05(10) (see footnote j) of the Criminal Code (see footnote k), that the Minister of Public Safety and Emergency Preparedness completed the review on November 20, 2016.

Ralph Goodale
Minister of Public Safety and Emergency Preparedness

[52-1-o]

GLOBAL AFFAIRS CANADA

Consultations on the fifth review of the Record of Discussion on Trade in Pharmaceutical Products

The Government of Canada is seeking the views of Canadians on a proposed fifth review of the 1994 Record of Discussion on Trade in Pharmaceutical Products (the “arrangement”) concluded among the following World Trade Organization (WTO) members: Canada, the European Union (EU), Japan, Macao (China), Norway, Switzerland, and the United States.

Background

Pursuant to the 1994 arrangement, participating WTO members have eliminated their duties, on a Most Favoured Nation basis, for specified pharmaceutical ingredients and intermediates.

The Record of Discussion was notified by the participating WTO members on March 25, 1994, and covered over 6 000 pharmaceutical-related products. To expand the coverage of tariff elimination to new pharmaceutical-related products developed after 1994, the Record of Discussion provides for the periodic review of the product coverage. Four earlier reviews occurred in 1996, 1998, 2007 and 2010. As a result of the reviews, the arrangement currently covers nearly 9 000 pharmaceutical-related products.

With respect to a fifth review of the arrangement, it has been suggested that the coverage of the arrangement be expanded to include additional compounds published by the World Health Organization (WHO) as Proposed International Nonproprietary Names (lists are available at www.who.int/medicines/publications/druginformation/innlists/en/).

Submissions by interested parties

The Government of Canada is seeking to identify the interests of Canadians in terms of product coverage as well as any concerns with the proposed elimination of Canadian tariffs for these products. To help inform this process, the Government is embarking on a public consultation process to give all interested stakeholders an opportunity to provide input. Interested parties wishing to contribute to this process are invited to provide responses to the following three questions:

  1. Do you support the proposed fifth review of the product scope of the Record of Discussion on the Trade in Pharmaceutical Products? Please provide a rationale for your response.
  2. Do you face tariff barriers in any participant countries with respect to exports of pharmaceutical ingredients or intermediates? If so, are they related to specific pharmaceutical ingredients or intermediates? Please provide the Harmonized System (HS) subheading codes.
  3. Do you have any views on the elimination of Canadian import tariffs on the pharmaceutical ingredients and intermediates listed by the WHO? If so, please provide a description of the ingredients or intermediates and their HS subheading codes.

The deadline for receiving input and comments is March 10, 2017. Please be advised that any information received as a result of this consultation will be considered public information, unless explicitly designated as private. Submissions should include the contributor’s name and address and, if applicable, his or her organization, institution or business.

Additional information

For more information on the Record of Discussions of the Trade in Pharmaceutical Products, please consult: https://www.wto.org/gatt_docs/English/SULPDF/91770009.pdf.

Contact points

Questions and contributions may be sent by mail or email to WTO Pharmaceutical Initiative, Tariffs and Goods Market Access Division (TPG), Global Affairs Canada, 111 Sussex Drive, Ottawa, Ontario K1A 0G2; email: tpg@international.gc.ca.

Questions or comments regarding the Canadian tariffs should be sent by mail or email to WTO Pharmaceutical Initiative, International Trade Policy Division, Department of Finance, 90 Elgin Street, 14th Floor, Ottawa, Ontario K1A 0G5; email: fin.tariff-tarif.fin@canada.ca.

[52-1-o]

OFFICE OF THE SUPERINTENDENT OF FINANCIAL INSTITUTIONS

INSURANCE COMPANIES ACT

Brookfield Annuity Company — Order to commence and carry on business

Notice is hereby given of the issuance, pursuant to subsection 53(1) of the Insurance Companies Act, of an order to commence and carry on business authorizing Brookfield Annuity Company, and, in French, La Compagnie de Rentes Brookfield, to commence and carry on business, effective October 3, 2016.

December 8, 2016

Jeremy Rudin
Superintendent of Financial Institutions

[52-1-o]

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. Moving forward, the Government of Canada will use an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous Canadians and minority groups are properly represented in positions of leadership. We will continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council Appointments website (http://www.appointmentsnominations.gc.ca/slctnPrcs.asp?menu=1&lang=eng).

Position

Organization

Closing date

Chairperson

Canadian Centre on Substance Abuse

January 16, 2017

Director

Canadian Centre on Substance Abuse

January 16, 2017

Full-time and part-time members

Canadian Human Rights Tribunal

January 9, 2017

Members

Canadian Institutes of Health Research

January 16, 2017

Chairperson

Canadian Museum for Human Rights

January 23, 2017

Trustees

Canadian Museum for Human Rights

January 9, 2017

Chairperson

Canadian Museum of History

January 23, 2017

Trustees

Canadian Museum of History

January 9, 2017

Vice-Chairperson

Canadian Museum of History

January 23, 2017

Chairperson

Canadian Museum of Immigration at Pier 21

January 23, 2017

Trustees

Canadian Museum of Immigration at Pier 21

January 9, 2017

Chairperson

Canadian Museum of Nature

January 23, 2017

Trustees

Canadian Museum of Nature

January 9, 2017

Permanent Members

Canadian Nuclear Safety Commission

January 16, 2017

Chief Science Advisor

Innovation, Science and Economic Development Canada

January 27, 2017

Chairperson

National Gallery of Canada

January 23, 2017

Trustees

National Gallery of Canada

January 9, 2017

Vice-Chairperson

National Gallery of Canada

January 23, 2017

Members

National Film Board

January 15, 2017

Trustees

National Museum of Science and Technology

January 9, 2017

Commissioner of Lobbying

Office of the Commissioner of Lobbying

January 9, 2017

Commissioner of Official Languages for Canada

Office of the Commissioner of Official Languages

January 9, 2017

Conflict of Interest and Ethics Commissioner

Office of the Conflict of Interest and Ethics Commissioner

January 9, 2017

Chairperson

Payment in Lieu of Taxes Dispute Advisory Panel

January 15, 2017

Members

Payment in Lieu of Taxes Dispute Advisory Panel

January 15, 2017

Chief Public Health Officer

Public Health Agency of Canada

February 12, 2017

Member

Telefilm Canada

January 15, 2017

Upcoming opportunities

New opportunities that will be posted in the coming weeks.

Position

Organization

President (Chief Executive Officer)

Atomic Energy of Canada Limited

Commissioner for Workers

Canada Employment Insurance Commission

Chairperson

Canada Foundation for Innovation

President

Canadian Centre for Occupational Health and Safety

Chairperson

Canadian International Trade Tribunal

Directors

Canadian Race Relations Foundation

Citizenship Judges

Citizenship Commission

Directors

First Nations Financial Management Board

Clerk of the House of Commons

House of Commons

Sergeant-at-Arms

House of Commons

Directors

Jacques Cartier and Champlain Bridges Incorporated

Members

National Arts Centre Corporation

Chairperson

National Battlefields Commission

Commissioner

National Battlefields Commission

Full-time Member

National Energy Board

Director of Public Prosecutions

Office of the Director of Public Prosecutions

Procurement Ombudsman

Office of the Procurement Ombudsman

Executive Vice-Chairperson and Member

Parole Board of Canada

Chairperson

Patented Medicine Prices Review Board

Member

Patented Medicine Prices Review Board

Directors

Royal Canadian Mint

Chairperson and Member

Standards Council of Canada

Ongoing opportunities

Opportunities posted on an ongoing basis.

Position

Organization

Full-time and Part-time Members

Immigration and Refugee Board

Members — All regional divisions (full-time positions and part-time positions)

Parole Board of Canada

Full-time and Part-time Members (Appeal Division)

Social Security Tribunal

Full-time and Part-time Members (General Division — Employment Insurance Section)

Social Security Tribunal

Full-time and Part-time Members (General Division — Income Security Section)

Social Security Tribunal

[52-1-o]

BANK OF CANADA

Statement of financial position as at November 30, 2016

(Millions of dollars) Unaudited

ASSETS

Cash and foreign deposits

 

14.6

Loans and receivables

Securities purchased under resale agreements

7,002.4

 

Advances to members of Payments Canada (see footnote *)

 

Advances to governments

 

Other receivables

6.3

 
   

7,008.7

Investments

Treasury bills of Canada

16,646.1

 

Government of Canada bonds

79,074.1

 

Other investments

403.7

 
   

96,123.9

Property and equipment

 

552.3

Intangible assets

 

34.4

Other assets

 

35.6

 

103,769.5


LIABILITIES AND EQUITY

Bank notes in circulation

 

77,726.9

Deposits

Government of Canada

22,548.9

 

Members of Payments Canada

488.7

 

Other deposits

1,847.3

 
   

24,884.9

Liabilities in foreign currencies

Government of Canada

 

Other

 
   

Other liabilities

Securities sold under repurchase agreements

 

Other liabilities

661.6

 
   

661.6

   

103,273.4

Equity

Share capital

5.0

 

Statutory and special reserves

125.0

 

Available-for-sale reserve

366.1

 

Actuarial gains reserve

 

Retained earnings

 
   

496.1

103,769.5

I declare that the foregoing return is correct according to the books of the Bank.

Ottawa, December 15, 2016

Carmen Vierula
Chief Financial Officer and Chief Accountant

I declare that the foregoing return is to the best of my knowledge and belief correct, and shows truly and clearly the financial position of the Bank, as required by section 29 of the Bank of Canada Act.

Ottawa, December 15, 2016

Stephen S. Poloz
Governor

[52-1-o]